Lilly Endowment Sells 300,000 Shares of Eli Lilly, Reducing Stake by 10%

Lilly Endowment, a charitable foundation owning more than 10% of Eli Lilly & Co. (NYSE: LLY), sold approximately 300,000 shares of Eli Lilly common stock in open‐market transactions on January 7, 2026. The shares traded at about $1,085 to $1,117 each, yielding total proceeds of roughly $329 million (around KRW 430 billion). After the sale, the foundation’s direct stake edged down to about 91.9 million shares. In its filing, Lilly Endowment stressed that the large‐scale sale was for portfolio management purposes and was unrelated to executive compensation.

Eli Lilly had earlier raised its third-quarter 2025 earnings guidance, driven by strong sales of its obesity treatment Zepbound and diabetes therapy Mounjaro, and lifted its full-year revenue forecast to around $63 billion. Supported by these growth expectations, the company surpassed a $1 trillion market capitalization in November 2025—the first pharmaceutical firm to reach that milestone. (Source: biopharmadive.com)

Headquartered in Indianapolis, Indiana, Eli Lilly is a global pharmaceutical company with multiple blockbuster drugs in diabetes, obesity, and oncology. The Lilly Endowment, founded by the Lilly family, is a major philanthropic organization that has long funded education, religious, and community initiatives through dividends and share sales of its Eli Lilly holdings.